FULC Fulcrum Therapeutics, Inc. Stock Quote

FULC [NASD]

Index	-	P/E	-	EPS (ttm)	-2.48	Insider Own	0.30%	Shs Outstand	32.64M	Perf Week	-16.67%
Market Cap	948.56M	Forward P/E	-	EPS next Y	-2.70	Insider Trans	-44.06%	Shs Float	17.56M	Perf Month	-25.27%
Income	-73.30M	PEG	-	EPS next Q	-0.65	Inst Own	74.30%	Short Float	11.76%	Perf Quarter	129.71%
Sales	15.20M	P/S	62.41	EPS this Y	29.50%	Inst Trans	10.37%	Short Ratio	0.60	Perf Half Y	97.94%
Book/sh	3.40	P/B	6.78	EPS next Y	-4.20%	ROA	-51.80%	Target Price	34.86	Perf Year	110.80%
Cash/sh	3.05	P/C	7.55	EPS next 5Y	6.40%	ROE	-66.80%	52W Range	6.85 - 33.10	Perf YTD	96.75%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-75.20%	52W High	-29.69%	Beta	-
Dividend %	-	Quick Ratio	5.70	Sales past 5Y	-	Gross Margin	-	52W Low	239.71%	ATR	2.08
Employees	73	Current Ratio	5.70	Sales Q/Q	120.00%	Oper. Margin	-	RSI (14)	38.64	Volatility	7.93% 7.82%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	8.40%	Profit Margin	-	Rel Volume	0.13	Prev Close	23.04
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 10 BMO	Payout	-	Avg Volume	3.44M	Price	23.27
Recom	2.00	SMA20	-14.13%	SMA50	-10.59%	SMA200	59.32%	Volume	103,803	Change	1.00%

Aug-11-21

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$12 → $34

Apr-26-21

Resumed

Credit Suisse

Outperform

$26

Mar-22-21

Initiated

Credit Suisse

Outperform

$26

Mar-02-21

Initiated

Stifel

Buy

$18

Oct-16-20

Initiated

Piper Sandler

Overweight

$22

Aug-12-20

Reiterated

H.C. Wainwright

Buy

$28 → $20

Aug-12-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$11

Aug-12-20

Downgrade

BofA Securities

Neutral → Underperform

$11

Jun-19-20

Downgrade

BofA/Merrill

Buy → Neutral

$19 → $23

Jun-17-20

Initiated

BTIG Research

Buy

$27

Oct-03-19

Initiated

H.C. Wainwright

Buy

$21

Aug-12-19

Initiated

BofA/Merrill

Buy

$19

Oct-14-21 10:05AM	Can Fulcrum Therapeutics, Inc. (FULC) Climb 31% to Reach the Level Wall Street Analysts Expect? Zacks
Oct-01-21 07:00AM	Fulcrum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-21-21 01:59PM	Shares Of Fulcrum Therapeutics Inc. Rise Above Previous 52-Week High Benzinga
Sep-20-21 07:00AM	Fulcrum Therapeutics Announces Multiple Presentations During the Virtual Congress of the World Muscle Society GlobeNewswire
Sep-10-21 07:00AM	Fulcrum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-08-21 07:00AM	Fulcrum Therapeutics Appoints Mel Hayes as Chief Commercial Officer GlobeNewswire -5.34%
Sep-02-21 07:00AM	Fulcrum Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-23-21 06:47AM	2 Soaring Biotech Stocks With More Fuel in the Tank Motley Fool
Aug-16-21 04:01PM	Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares GlobeNewswire -5.19%
11:51AM	Is Fulcrum Stock a Buy Right Now? This Is What You Need to Know TipRanks
06:16AM	News Flash: Analysts Just Made An Incredible Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts Simply Wall St.
Aug-12-21 01:33AM	Earnings Beat: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St. +11.14%
Aug-11-21 10:09PM	Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock GlobeNewswire +7.62%
04:06PM	Why Fulcrum Therapeutics Popped Again on Tuesday Motley Fool
Aug-10-21 04:24PM	Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +125.33%
04:04PM	Fulcrum Stock Nearly Triples Why Shares Went Gangbusters On Sickle Cell Drug Investor's Business Daily
10:56AM	Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today Motley Fool
09:05AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:01AM	Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results GlobeNewswire
07:00AM	Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease GlobeNewswire
Aug-04-21 07:00AM	Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET GlobeNewswire
Aug-03-21 03:00PM	Will Fulcrum Therapeutics, Inc. (FULC) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-30-21 11:14AM	Were Hedge Funds Right About Fulcrum Therapeutics, Inc. (FULC)? Insider Monkey
Jul-01-21 01:25AM	Independent Director James Geraghty Just Bought 12% More Shares In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Simply Wall St.
Jun-24-21 07:00AM	Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function GlobeNewswire
Jun-21-21 07:00AM	Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC) GlobeNewswire
May-12-21 04:19PM	Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation Benzinga
07:00AM	Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD) GlobeNewswire
02:08AM	News Flash: Analysts Just Made A Huge Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts Simply Wall St.
May-07-21 07:00AM	Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference GlobeNewswire
05:09AM	A Look At Fulcrum Therapeutics' (NASDAQ:FULC) Share Price Returns Simply Wall St.
May-06-21 08:55AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates Zacks +5.06%
07:01AM	Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results GlobeNewswire
07:00AM	Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer GlobeNewswire
06:15AM	Fulcrum Therapeutics Inc to Host Earnings Call ACCESSWIRE
Apr-29-21 07:00AM	Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET GlobeNewswire
Apr-09-21 01:15PM	Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference GlobeNewswire
Mar-24-21 09:29AM	Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development GlobeNewswire
Mar-18-21 11:30AM	Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference GlobeNewswire -7.66%
Mar-04-21 08:25AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates Zacks -14.32%
07:01AM	Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
07:00AM	Fulcrum Therapeutics Announces CEO Transition GlobeNewswire
06:15AM	Fulcrum Therapeutics Inc to Host Earnings Call ACCESSWIRE
Feb-26-21 07:00AM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET GlobeNewswire
07:00AM	Fulcrum Therapeutics Recognizes Rare Disease Day 2021 GlobeNewswire
Feb-19-21 07:00AM	Fulcrum Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +8.27%
Feb-17-21 02:47AM	What Type Of Shareholders Own The Most Number of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares? Simply Wall St.
Jan-22-21 04:00PM	Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares GlobeNewswire
Jan-19-21 10:34PM	Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire +6.64%
04:01PM	Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
04:00PM	Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer GlobeNewswire
Jan-06-21 07:00AM	Fulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 Conference GlobeNewswire
Dec-09-20 09:43PM	Is FULC A Good Stock To Buy Now? Insider Monkey
07:00AM	Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease GlobeNewswire
Dec-05-20 10:00AM	Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire
Dec-03-20 08:00AM	Pandion Therapeutics Appoints Katina Dorton to its Board of Directors GlobeNewswire
Nov-16-20 03:18AM	Here's Why We're Not Too Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Situation Simply Wall St.
Nov-13-20 07:30AM	Fulcrum Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +5.59%
Nov-10-20 11:30AM	Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates Zacks
08:23AM	Fulcrum Therapeutics' (FULC) Shares March Higher, Can It Continue? Zacks
07:00AM	Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results GlobeNewswire
Nov-09-20 08:31AM	Why Fulcrum Therapeutics (FULC) Might Surprise This Earnings Season Zacks -8.31%
Nov-04-20 04:01PM	Fulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire +7.26%
Nov-03-20 07:00AM	Fulcrum Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, November 10, 2020 at 8:00 a.m. ET GlobeNewswire +20.39%
Oct-31-20 08:00AM	Kaskela Law LLC Announces Stockholder Investigation of Fulcrum Therapeutics, Inc. - FULC ACCESSWIRE
Oct-05-20 07:00AM	Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease GlobeNewswire +9.18%
Oct-01-20 07:00AM	Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society GlobeNewswire
Sep-25-20 02:15PM	Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting GlobeNewswire +7.03%
Sep-08-20 07:00AM	Fulcrum Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +7.47%
Aug-18-20 02:49PM	Fulcrum Therapeutics'(NASDAQ:FULC) Share Price Is Down 33% Over The Past Year. Simply Wall St. +6.11%
Aug-11-20 07:01AM	Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results GlobeNewswire -48.01%
07:00AM	Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD) GlobeNewswire
Aug-10-20 09:43AM	Why Earnings Season Could Be Great for Fulcrum Therapeutics (FULC) Zacks
Aug-06-20 07:00AM	Fulcrum Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-05-20 07:00AM	Fulcrum Therapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 11, 2020 at 8:00 a.m. ET GlobeNewswire +6.50%
Jul-28-20 07:54AM	Fulcrum Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-21-20 07:30AM	MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies GlobeNewswire
Jun-24-20 08:56AM	Is Fulcrum Therapeutics (FULC) Stock a Solid Choice Right Now? Zacks +11.96%
07:47AM	Fulcrum Therapeutics begins trial of muscle disorder drug for COVID-19 patients Reuters
07:00AM	Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients GlobeNewswire
Jun-12-20 06:45PM	Do Hedge Funds Love Fulcrum Therapeutics, Inc. (FULC)? Insider Monkey
Jun-10-20 07:01AM	Fulcrum Therapeutics Completes $68.5 Million Private Placement GlobeNewswire -9.74%
07:00AM	Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19 GlobeNewswire
May-21-20 07:00AM	Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform GlobeNewswire
May-14-20 09:42AM	Fulcrum Therapeutics, Inc. (FULC) Shares March Higher, Can It Continue? Zacks
May-13-20 09:31PM	Fulcrum Therapeutics, Inc. (FULC) Q1 2020 Earnings Call Transcript Motley Fool +10.53%
07:00AM	Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results GlobeNewswire
May-11-20 07:00AM	Fulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference GlobeNewswire +19.55%
May-07-20 07:00AM	Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8:00 a.m. ET GlobeNewswire
Apr-13-20 07:00AM	Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease GlobeNewswire -6.32%
Apr-02-20 07:00AM	Fulcrum Therapeutics Provides Business Update on Impact of COVID-19 GlobeNewswire
Mar-24-20 02:20PM	Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) GlobeNewswire
Mar-05-20 07:00AM	Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-28-20 07:00AM	Fulcrum Therapeutics Joins in Effort to Reframe Rare to Commemorate Rare Disease Day 2020 GlobeNewswire
Feb-26-20 07:00AM	Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD) GlobeNewswire +13.11%
Feb-25-20 08:00AM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Thursday, March 5, 2020 at 8:00 a.m. ET GlobeNewswire
Feb-20-20 08:01AM	Fulcrum Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +10.30%
Jan-29-20 08:01AM	Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio GlobeNewswire
Jan-06-20 07:00AM	Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors GlobeNewswire
Dec-30-19 07:30AM	Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement Business Wire

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and -thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stuart Bryan	See Remarks	Aug 11	Option Exercise	7.84	28,000	219,520	28,000	Aug 12 04:20 PM
Stuart Bryan	See Remarks	Aug 11	Sale	23.75	28,000	665,000	0	Aug 12 04:20 PM
Moxham Christopher	Chief Scientific Officer	Aug 10	Option Exercise	7.84	51,785	405,994	31,071	Aug 12 04:20 PM
Stuart Bryan	See Remarks	Aug 10	Option Exercise	7.84	32,000	250,880	32,000	Aug 12 04:20 PM
Moxham Christopher	Chief Scientific Officer	Aug 10	Sale	17.60	51,785	911,416	0	Aug 12 04:20 PM
Stuart Bryan	See Remarks	Aug 10	Sale	17.50	32,000	560,000	0	Aug 12 04:20 PM
Thomson Peter G.	VP Finance & Accounting	Jun 28	Buy	9.00	2,300	20,700	2,300	Jun 29 04:15 PM
Oltmans Curtis Gale	SVP, General Counsel	Jun 28	Buy	9.01	1,088	9,803	1,088	Jun 29 04:16 PM
Morabito Christopher	Chief Medical Officer	Jun 28	Buy	9.16	1,100	10,076	1,100	Jun 29 04:16 PM
GERAGHTY JAMES A	Director	Jun 28	Buy	9.16	10,000	91,600	90,714	Jun 29 04:15 PM
Gould Robert J	See Remarks	Mar 16	Sale	12.43	789	9,806	506,630	Mar 17 04:30 PM
Gould Robert J	See Remarks	Mar 15	Sale	12.13	9,211	111,773	507,419	Mar 17 04:30 PM
Thomson Peter G.	VP Finance & Accounting	Feb 22	Option Exercise	7.84	5,000	39,200	20,212	Feb 24 04:30 PM
Thomson Peter G.	VP Finance & Accounting	Feb 22	Sale	14.72	5,000	73,582	15,212	Feb 24 04:30 PM
Gould Robert J	See Remarks	Feb 16	Sale	14.27	8,215	117,197	516,630	Feb 18 04:30 PM
Thomson Peter G.	VP Finance & Accounting	Jan 21	Sale	14.00	6,607	92,498	15,212	Jan 25 04:30 PM
Gould Robert J	See Remarks	Jan 20	Sale	12.08	10,000	120,826	524,845	Jan 22 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience